NTproBNP results are used as an aid to assist in the diagnosis and assessment of severity of congestive heart failure (CHF) and risk stratification in patients with acute coronary syndromes (ACS) [1-3].
Outpatients with symtoms suggestive of heart failure show a cut-off value for NTproBNP of 125 pg/ml. NTproBNP values < 125 pg/ml rule out ventricular dysfunction in patients with symptoms suggestive of heart failure.
The International Collaborative of NTproBNP Study revealed in 1256 patients presenting with acute shortness of breath to emergency departments of four hospitals cutpoint of 300 pg/ml for ruling out acute heart failure in the emergency room setting. To identify acute heart failure age-related cutpoints of 450, 900 and 1800 pg/ml for ages < 50, 50-75, and > 75 years were defined [2,3].
Risk stratification with NYHA classification
Blood samples were obtained from 72 patients diagnosed with congested heart failure (CHF). The descriptive studies and New York Heart Association (NYHA) functional classes are provided.
- Nielsen LS et al. N-terminal pro-brain natriuretic peptide for discriminating between cardiac and non-cardiac dyspnea. Eur heart J Fail 2004;6:63-70.
- Januzzi JL et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients. The International Collaborative of NT-proBNP Study. Eur Heart J 2006;27:330-7
- M. Zaninotto et al. “PATHFAST NtproBNP: A multicenter evaluation of a new point of care assay.” Clin Chem Lab Med 2010; 48:1029-1034